ArticleNature communications2021
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors.
Registry-linked trialAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04338360 (Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19), which is not on this map. Cited by 40 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials.Frontiers in immunology · 2022Pooled it
- Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy.Cell reports. Medicine · 2022Trial
- Trial
- Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial).BMJ open · 2022Trial
- Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection.Scientific reports · 2022Trial
- Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical center.PloS one · 2022Trial
- A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.The Journal of clinical investigation · 2021Trial
- The Importance of Geographic Proximity of Convalescent Plasma Donors.Current topics in microbiology and immunology · 2025Review
- Evidence for the Efficacy of COVID-19 Convalescent Plasma.Current topics in microbiology and immunology · 2025Review
- Generating the Evidence Base for Convalescent Plasma Use for a New Infectious Disease.Current topics in microbiology and immunology · 2025Review
- Using Passive Antibody Therapies in the Next Pandemic.Current topics in microbiology and immunology · 2025Review
- Development of a nomogram for high antibody titre of COVID-19 convalescent plasma.Epidemiology and infection · 2024Article
- Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Creating a plasma coordination center to support COVID-19 outpatient trials across a national network of hospital blood banks.Journal of clinical and translational science · 2024Article
- Review
- Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis.Mayo Clinic proceedings. Innovations, quality & outcomes · 2023Article
- Design of VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1): A double-blind, randomized placebo-controlled trial of COVID-19 convalescent plasma in hospitalized patients with early respiratory compromise.Contemporary clinical trials communications · 2023Article
- Exercise and Experiments of Nature.Comprehensive Physiology · 2023Article
- Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors.
Katie L Kunze *Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.ORCID 0000-0001-6850-6823
Patrick W Johnson *Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-8365-1375
Noud van HelmondDepartment of Anesthesiology, Cooper Medical School of Rowan University, Cooper University Health Care, Camden, NJ, USA.ORCID 0000-0003-1395-4754
Jonathon W SenefeldDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8116-3538
Molly M PetersenDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.ORCID 0000-0002-7779-4940
Stephen A KlassenDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.
Chad C WigginsDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-6458-0142
Allan M KlompasDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8852-4666
Katelyn A BrunoDepartment of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-8980-6059
John R MillsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-1025-4760
Elitza S TheelDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-6886-2294
Matthew R BurasDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.ORCID 0000-0001-6503-0989
Michael A GolafsharDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.ORCID 0000-0001-7666-7782
Matthew A SextonDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-6825-7297
Juan C Diaz SotoDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-9173-1308
Sarah E BakerDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-9647-7660
John R A ShepherdDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.
Nicole C VerdunCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Peter MarksCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.ORCID 0000-0001-5619-4404
Nigel S PanethDepartment of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, MI, USA.
DeLisa FairweatherDepartment of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0003-3093-1810
R Scott WrightDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-0625-0444
Camille M van BuskirkDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Jeffrey L WintersDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8654-3732
James R StubbsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-3270-4913
Katherine A SeneseDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-9413-5664
Michaela C PletschDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-1440-0614
Zachary A BuchholtzDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5450-6072
Robert F ReaDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Vitaly HerasevichDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-0214-0651
Emily R WhelanDepartment of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-0410-0549
Andrew J ClayburnDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.
Kathryn F LarsonDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-2565-3318
Juan G RipollDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-4908-9774
Kylie J AndersenDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8668-2871
Elizabeth R LesserDepartment of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.
Matthew N P VogtDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-0721-8451
Joshua J DennisDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.
Riley J RegimbalDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.
Philippe R BauerDepartment of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8429-3581
Janis E BlairDepartment of Internal Medicine, Division of Infectious Diseases, Mayo Clinic, Phoenix, AZ, USA.ORCID 0000-0003-2267-1473
Arturo CasadevallDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0002-9402-9167
Rickey E CarterDepartment of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-0818-273X
Michael J JoynerDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA. joyner.michael@mayo.edu.ORCID 0000-0002-7135-7643
Funding
Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4MDIABETES AND METABOLISMT32DK007352 · NIDDK · MAYO CLINIC ROCHESTER · PI MICHAEL D. JENSEN · 1986 to 2026
$9.4MSex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's DiseaseU54AG044170 · NIA · MAYO CLINIC ROCHESTER · PI KAPOOR, EKTA · 2018 to 2022
$7.7MSynergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4MVariant Hemoglobin and Cardiorespiratory Regulation in HumansR35HL139854 · NHLBI · MAYO CLINIC ROCHESTER · PI JOYNER, MICHAEL J · 2018 to 2024
$5.8MConjugate vaccines for prevention and treatment of cryptococcosis - COVID-19 Revision SupplementR01AI152078 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2020 to 2024
$5.1MRole of viral mitophagosomes in driving sex differences in myocarditisR21AI145356 · NIAID · MAYO CLINIC JACKSONVILLE · PI FAIRWEATHER, DELISA, SIN, JON · 2019 to 2020
$463kAdipose-derived biogenic nanoparticles for treatment of myocarditis/DCM(MPDPI)R21AI152318 · NIAID · MAYO CLINIC JACKSONVILLE · PI FAIRWEATHER, DELISA, WOLFRAM, JOY · 2020 to 2021
$430kSex differences in exercise-induced mitochondrial function during viral myocarditisR21AI154927 · NIAID · MAYO CLINIC JACKSONVILLE · PI FAIRWEATHER, DELISA · 2020 to 2021
$403kSkeletal muscle performance and cellular adaptations to high hemoglobin-oxygen affinityF32HL154320 · NHLBI · MAYO CLINIC ROCHESTER · PI SENEFELD, JONATHON · 2020 to 2021
$117kNCATS NIH HHS UL1 TR002377NHLBI NIH HHS F32 HL154320NHLBI NIH HHS R01 HL059842NHLBI NIH HHS R35 HL139854NIAID NIH HHS R01 AI152078NIAID NIH HHS R21 AI145356NIAID NIH HHS R21 AI152318NIAID NIH HHS R21 AI154927NIA NIH HHS U54 AG044170NIDDK NIH HHS T32 DK007352
Abstract
Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma likely reflects the antigenic composition of local viral strains, we hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity. Results of a series of modeling techniques applied to approximately 28,000 patients from the Expanded Access to Convalescent Plasma program (ClinicalTrials.gov number: NCT04338360) support this hypothesis. This work has implications for the interpretation of clinical studies, the ability to develop effective COVID-19 treatments, and, potentially, for the effectiveness of COVID-19 vaccines as additional locally-evolving variants continue to emerge.
Indexed as
AdolescentAdultAgedAntibodies, ViralAntibody SpecificityAntigenic VariationBlood DonorsCOVID-19COVID-19 SerotherapyFemaleHumansImmunization, PassiveMaleMiddle AgedPlasmaSARS-CoV-2Antibodies, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT04338360ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.